More Info Physical Appearance Stability Solubility Amino Acid Sequence Background GHK-Cu is located in human plasma and has an ability to modify gene expression to a healthier state, influencing more than 4,000 human genes
For patients without diabetes using Wegovy for weight management: Routine blood glucose monitoring is not typically required , as hypoglycaemia risk is low Patients should be counselled about maintaining adequate nutritional intake despite appetite suppression Report any symptoms suggestive of hypoglycaemia (tremor, sweating, confusion) to their healthcare provider Annual HbA1c testing may be appropriate for those with prediabetes or metabolic syndrome For patients with type 2 diabetes on combination therapy: Self-monitoring of blood glucose (SMBG) frequency should be individualised based on hypoglycaemia risk Those on insulin or sulphonylureas should monitor more frequently, particularly during Wegovy initiation and dose escalation Continuous glucose monitoring (CGM) may be considered for high-risk individuals or those with impaired awareness, in line with NICE and NHS England access criteria Medication review and adjustment sulphonylurea and insulin doses often require reduction when starting GLP-1 therapy
Integrating Medication Into a Comprehensive Weight Management Plan While medication plays a powerful role, it is most effective when integrated into a broader, professionally guided weight management strategy
Eden does not manufacture, own, or dispense any medications, including semaglutide
G.RussoM.et al (2022)
Keeping an eye on platelet and B12 levels is also important to adjust treatment as needed
